Skip to main content
. 2003 May 1;111(9):1329–1338. doi: 10.1172/JCI16750

Figure 7.

Figure 7

MOR agonists prevent wasting disease and colitis in SCID mice after T cell transfer. Weekly evaluation of change in weight (mean ± SEM) (a) and percent survival (b) in SCID mice during the 4 weeks after cell transfer. Untreated SCIDmice after transfer of both CD4+CD45RBlo and CD45RBhi T cells (diamonds) or after reconstitution with CD4+CD45RBhi T cells (squares). SCIDmice reconstituted with CD4+ CD45RBhi T cells and treated with DALDA (10–2 mg/kg/d) (triangles) or DAMGO (10–3 mg/kg/d) (circles). (c) Macroscopic scores (mean ± SEM) evaluated 4 weeks after T cell transfer in control SCID mice reconstituted with both CD4+CD45RBlo and CD45RBhi T cells (Hi + Lo) and in SCID mice with colitis reconstituted with CD4+CD45RBhi T cells without any treatment (Hi) or after subcutaneous administration of DALDA (10–2 mg/kg/d) (Hi + D) or DAMGO (10–3 mg/kg/d) (Hi + Do). (d and e) Representative macroscopic lesions in control SCID mice after transfer of CD4+CD45RBlo and CD45RBhi (RBhi) T cells (control) and in SCID mice with colitis after reconstitution with CD4+CD45RBhi T cells without any treatment (RBhi) or after subcutaneous administration of DALDA (10–2 mg/kg/d) (RBhi + DALDA). SM, splenomegaly.